We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Results for
"[search-keyword]"
Sponsor content
309 result(s) found, displaying 1 to 10
-
Prescription medicine registrationActive ingredients: osimertinib mesilate.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ARX-Ticagrelor ticagrelor 90 mg tablet blister pack.
-
Australian Public Assessment Report (AusPAR)Lokelma (sodium zirconium cyclosilicate hydrate) has been approved for the treatment of hyperkalaemia in adult patients.
-
Australian Public Assessment Report (AusPAR)Enhertu (trastuzumab deruxtecan) has been approved to treat adult patients with unresectable or metastatic HER2-low breast cancer.
-
Sep-2024Prescription medicine evaluationActive ingredient: trastuzumab deruxtecan.
-
Sep-2024Prescription medicine evaluationActive ingredient: sipavibart.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SIDAPVIA 10/100 dapagliflozin 10 mg (as propanediol monohydrate)/sitagliptin 100 mg (as phosphate monohydrate) film coated tablets blister pack.
-
Australian Public Assessment Report (AusPAR)Sidapvia (dapagliflozin+sitagliptin), a new drug combination, has been approved to treat type 2 diabetes mellitus in adults, as an adjunct to diet and exercise to improve glycaemic control.
-
-
Australian Public Assessment Report (AusPAR)Lynparza (olaparib) has been approved for the treatment of BRCA-mutated HER2-negative high risk early breast cancer and metastatic castration-resistant prostate cancer.